SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)
$TOI
Medical/Nursing Services
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2024 | $2.50 | Buy | Jefferies |
| 9/14/2022 | $7.00 | Buy | Guggenheim |
| 8/15/2022 | $10.00 | Buy | Jefferies |
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)
CERRITOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and nine months ended September 30, 2024. Recent Operational Highlights Include 79.9% increase in Dispensary segment revenue compared to prior year quarterWelcomed Rob Carter, as our new Chief Financial Officer3 new capitation contracts signed across 2 states including both medical and radiation oncology services, which brings to 13 our 2024 newly signed capitation contractsStarted second capitation contract in Florida directly with a health plan
CERRITOS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2024 financial results after the market close on Wednesday, November 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call an
CERRITOS, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and six months ended June 30, 2024 and updated its full year 2024 guidance. Recent Operational Highlights Include 76% increase in Dispensary segment revenue compared to prior year quarter3 new capitation contracts signed across 2 states including both medical and radiation oncology services, which brings our new 2024 newly signed capitation contracts to 10Exploring strategic alternatives to maximize shareholder value Second Quarter 2024 Financia
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
CERRITOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and nine months ended September 30, 2024. Recent Operational Highlights Include 79.9% increase in Dispensary segment revenue compared to prior year quarterWelcomed Rob Carter, as our new Chief Financial Officer3 new capitation contracts signed across 2 states including both medical and radiation oncology services, which brings to 13 our 2024 newly signed capitation contractsStarted second capitation contract in Florida directly with a health plan
CERRITOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) announced that they have received certification to begin administering Pluvicto therapy in their outpatient California radiation oncology practices. Pluvicto, a radiopharmaceutical used to treat certain types of metastatic prostate cancer, has previously been administered primarily in hospital settings. "We are ecstatic about the opportunity to offer this new therapeutic alternative to our patients," said Dr. Geoffrey Geiger, Medical Director of Radiation Oncology at TOI. "This aligns perfectly with TOI's mission to deliver state-of-the-art therapy in the community and p
CERRITOS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2024 financial results after the market close on Wednesday, November 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call an
10-Q - Oncology Institute, Inc. (0001799191) (Filer)
8-K - Oncology Institute, Inc. (0001799191) (Filer)
8-K - Oncology Institute, Inc. (0001799191) (Filer)
Jefferies resumed coverage of The Oncology Institute with a rating of Buy and set a new price target of $2.50
Guggenheim initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00
Jefferies initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $10.00
4 - Oncology Institute, Inc. (0001799191) (Issuer)
CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Hea
CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urolog
CERRITOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced that, by mutual agreement with the Board of Directors, Brad Hively will step down as Chief Executive Officer effective June 30, 2023. Dr. Daniel Virnich, the current President of TOI, will become CEO. Mr. Hively will transition to the role of Vice Chairman of the Board of Directors. Dr. Daniel Virnich has been with The Oncology Institute since 2020, initially as Chief Operating Officer before being promoted to President. He joined TOI from DaVita where he was most recently Pres
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effective July 5, 2024. NIO shares dipped 8.5% to $4.4550 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 120% to $0.3870 after gaining 6% on Wednesday. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) rose 70.5% to $4.65 after gaining around 14% on Wednesday. MediWound Ltd. (NASDAQ:MDWD) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday. Koss Corporation (NASDAQ:KOSS) shares climb
Gainers Nexalin Technology (NASDAQ:NXL) shares rose 55.8% to $1.62 during Tuesday's after-market session. The market value of their outstanding shares is at $12.0 million. Dynatronics (NASDAQ:DYNT) stock rose 14.74% to $0.4. The company's market cap stands at $2.1 million. Oncology Institute (NASDAQ:TOI) shares moved upwards by 10.8% to $0.45. The market value of their outstanding shares is at $33.5 million. SAB Biotherapeutics (NASDAQ:SABS) stock rose 8.94% to $2.8. The market value of their outstanding shares is at $25.8 million. Bone Biologics (NASDAQ:BBLG) shares moved upwards by 8.04% to $1.61. The company's market cap stands at $1.7 million. Virpax Pharmaceuticals (NASDAQ:VRPX) s
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results. Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from Benzinga Pro. Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers AERWINS Technologies Inc. (NASDAQ:AWIN) shares surged